Sign In
Buy ALNA
$0.0270
+0 (+0%)
At Close: Feb 07, 2023
Contrasting Allena Pharmaceuticals (NASDAQ:ALNA) & Audentes Therapeutics (NASDAQ:BOLD)
06:46am, Wednesday, 15'th Jan 2020
Allena Pharmaceuticals (NASDAQ:ALNA) and Audentes Therapeutics (NASDAQ:BOLD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of t
Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why
05:00pm, Tuesday, 14'th Jan 2020
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hedge Funds Have Never Been This Bullish On Allena Pharmaceuticals, Inc. (ALNA)
06:45pm, Monday, 16'th Dec 2019
Is Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite in
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
12:14pm, Thursday, 05'th Dec 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration o
Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
10:00pm, Wednesday, 04'th Dec 2019
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe
Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference
01:00pm, Monday, 25'th Nov 2019
NEWTON, Mass., Nov. 25, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.
Do Directors Own Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Shares?
11:19am, Monday, 18'th Nov 2019
A look at the shareholders of Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) can tell us which group is most powerful...
Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
01:01pm, Wednesday, 13'th Nov 2019
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
01:14pm, Friday, 08'th Nov 2019
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL
Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206
11:55am, Thursday, 07'th Nov 2019
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe
NEWTON, Mass., Oct. 17, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe
ALLN Walking Into Life for Bringing Various Applications - Coin News Asia
12:38pm, Thursday, 29'th Mar 2018
Airline and Life Networking Token (ALLN), the world's first digital airline encryption token, is born. Read more about it here at Coin News Asia.
Allena Pharmaceuticals Completes $53M Series C Financing |FinSMEs
04:36pm, Wednesday, 09'th Dec 2015
Allena Pharmaceuticals, Inc., a Newton, MA-based biopharmaceutical company focused on developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan dis
